Elotuzumab. targeting signaling lymphocytic activation molecule family 7 (SLAMF7). has been approved in combination with lenalidomide and dexamethasone (ELd) for relapsed/refractory multiple myeloma (MM) based on the findings of the phase III randomized trial ELOQUENT-2 (NCT01239797). Four-year follow-up analyses of ELOQUENT-2 have demonstrated that progression-free survival was 21% i... https://cosmeticssquadets.shop/product-category/back-scratchers/